SCHEDULE: Schornstein Boosts MEI Pharma Stake to 13.29% Amid Rebrand

Alexander Schornstein has increased his beneficial ownership in MEI Pharma, Inc. to 13.29% of common stock, coinciding with the company's rebranding to Lite Strategy, Inc.

Summary

• Alexander Schornstein reported beneficial ownership of 4,365,472 shares of MEI Pharma, Inc. common stock.
• This represents 13.29% of the company's outstanding common stock, based on 32,837,743 shares.
• The ownership includes 4,140,472 shares held directly by Schornstein and 225,000 shares held by Camino Capital GmbH, where Schornstein is the sole beneficial owner.
• The increase in ownership, exceeding ten percent, occurred on September 9, 2025, following several purchases between August 11, 2025, and September 9, 2025.
• The shares were acquired using personal funds and not for the purpose of changing or influencing the control of the issuer.
• MEI Pharma, Inc. changed its name to Lite Strategy, Inc. effective September 10, 2025, and will begin trading under the new symbol "LITS" on September 11, 2025.

Sentiment

Score: 7

Explanation: The filing indicates a significant increase in an individual investor's stake, which can be interpreted as a vote of confidence. However, it is primarily a regulatory disclosure of ownership and a previously announced name change, not an operational update.

Positives

• A significant individual investor, Alexander Schornstein, has increased his stake to 13.29%, indicating confidence in the company.
• The acquisition was made using personal funds, suggesting a direct commitment from the investor.

Future Outlook

No specific forward-looking statements or guidance are provided by company management in this ownership disclosure filing.

Industry Context

This filing primarily concerns a change in beneficial ownership and a corporate name change. The name change from 'MEI Pharma' to 'Lite Strategy' suggests a potential shift in strategic focus or a re-branding effort, possibly moving away from a purely pharmaceutical identity, which could impact its positioning within its former or new industry.

Corporate Governance

Stakeholder Impact

• Shareholders: Existing shareholders will see a significant individual investor increase their stake, potentially signaling confidence. They will also need to be aware of the company's name and ticker symbol change.
• Investors: Potential investors might view the increased stake by Alexander Schornstein as a positive indicator.
• Regulatory Authorities: The filing ensures transparency regarding significant ownership stakes, fulfilling regulatory requirements.

Next Steps

• Lite Strategy, Inc. will begin trading under the new symbol "LITS" on September 11, 2025.

Key Dates

Recommendation

The filing primarily discloses a significant increase in an individual's beneficial ownership and a corporate name change. While the increased stake by Alexander Schornstein could be seen as a positive signal of confidence, the filing lacks detailed operational or financial performance data to justify a strong buy or sell recommendation. A 'hold' recommendation is appropriate as investors should await further information on Lite Strategy, Inc.'s business strategy and financial performance before making a definitive investment decision.

Keywords

MEI Pharma, Lite Strategy, Alexander Schornstein, LITS, beneficial ownership, Schedule 13G, common stock, investor stake, corporate rebranding